Ann: Director Appointment-PYC.AX, page-10

I see things very differently.

I view it as extremely positive move for shareholders and the science.

PYC science is now moving to the next stage of drug development and it will require people who have done that before.
Dr Watts hasn't done that before and it is too expensive in such situations to have senior people learning on the job.
PYC also can't keep paying big salaries to people who aren't able to deliver commercial outcomes.
I would expect to see some new executive appointments in the near term and hoping the CV's will reflect some big pharma experience and higher level commercial contacts.